

# Brian T Fisher

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6331188/publications.pdf>

Version: 2024-02-01

149  
papers

4,442  
citations

186254

28  
h-index

118840

62  
g-index

153  
all docs

153  
docs citations

153  
times ranked

5437  
citing authors

#	ARTICLE	IF	CITATIONS
1	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020, 71, 1367-1376.	5.8	1,429
2	Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 2082-2094.	1.6	337
3	Effect of Levofloxacin Prophylaxis on Bacteremia in Children With Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 995.	7.4	136
4	Galactomannan, $\beta$ -D-Glucan, and Polymerase Chain Reaction–Based Assays for the Diagnosis of Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. <i>Clinical Infectious Diseases</i> , 2016, 63, 1340-1348.	5.8	123
5	Association of Social Distancing, Population Density, and Temperature With the Instantaneous Reproduction Number of SARS-CoV-2 in Counties Across the United States. <i>JAMA Network Open</i> , 2020, 3, e2016099.	5.9	115
6	Bronchoalveolar Lavage and Lung Biopsy in Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2015, 33, 501-509.	1.6	108
7	A Prospective, International Cohort Study of Invasive Mold Infections in Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2015, 4, 313-322.	1.3	86
8	Guideline for Antibacterial Prophylaxis Administration in Pediatric Cancer and Hematopoietic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2020, 71, 226-236.	5.8	84
9	Risk Factors for Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2018, 7, 191-198.	1.3	83
10	Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group. <i>Haematologica</i> , 2020, 105, 1879-1886.	3.5	83
11	Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children. <i>JAMA Pediatrics</i> , 2017, 171, e173219.	6.2	72
12	Classification of treatment-related mortality in children with cancer: a systematic assessment. <i>Lancet Oncology</i> , The, 2015, 16, e604-e610.	10.7	69
13	Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1673.	7.4	67
14	Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients. <i>Journal of Clinical Oncology</i> , 2020, 38, 3205-3216.	1.6	63
15	Role of Molecular Biomarkers in the Diagnosis of Invasive Fungal Diseases in Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2017, 6, S32-S44.	1.3	62
16	Trends in <i>Clostridium difficile</i> Infection and Risk Factors for Hospital Acquisition of <i>Clostridium difficile</i> among Children with Cancer. <i>Journal of Pediatrics</i> , 2013, 163, 699-705.e1.	1.8	61
17	A Multicenter Consortium to Define the Epidemiology and Outcomes of Inpatient Respiratory Viral Infections in Pediatric Hematopoietic Stem Cell Transplant Recipients. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2018, 7, 275-282.	1.3	53
18	Diagnostic Imaging and Invasive Fungal Diseases in Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2017, 6, S22-S31.	1.3	52

#	ARTICLE	IF	CITATIONS
19	Efficacy of antibiotic prophylaxis in patients with cancer and hematopoietic stem cell transplantation recipients: A systematic review of randomized trials. <i>Cancer Medicine</i> , 2019, 8, 4536-4546.	2.8	52
20	T2Candida Provides Rapid and Accurate Species Identification in Pediatric Cases of Candidemia. <i>American Journal of Clinical Pathology</i> , 2016, 145, 858-861.	0.7	50
21	Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2016, 34, 1537-1543.	1.6	47
22	Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2106-2118.	1.6	45
23	Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27747.	1.5	40
24	Galactomannan Antigen Testing for Diagnosis of Invasive Aspergillosis in Pediatric Hematology Patients. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2012, 1, 103-111.	1.3	39
25	Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to <i>Candida parapsilosis</i> : a retrospective observational cohort study of the Mycoses Study Group (MSG-12): Table A1. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3536-3539.	3.0	37
26	Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio <i>FLT3/ITD+</i> Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031. <i>Journal of Clinical Oncology</i> , 2022, 40, 2023-2035.	1.6	36
27	Poverty and Targeted Immunotherapy: Survival in Children's Oncology Group Clinical Trials for High-Risk Neuroblastoma. <i>Journal of the National Cancer Institute</i> , 2021, 113, 282-291.	6.3	33
28	Hospitalizations for Coccidioidomycosis at Forty-One Children's Hospitals in the United States. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, 243-247.	2.0	32
29	Using electronic medical record data to report laboratory adverse events. <i>British Journal of Haematology</i> , 2017, 177, 283-286.	2.5	31
30	Risk factors for renal failure in pediatric patients with acute myeloid leukemia: A retrospective cohort study. <i>Pediatric Blood and Cancer</i> , 2010, 55, 655-661.	1.5	29
31	The role of acuity of illness at presentation in early mortality in black children with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2017, 92, 141-148.	4.1	29
32	Invasive Fungal Disease in Pediatric Solid Organ Transplant Recipients. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2018, 7, 219-225.	1.3	28
33	The Effectiveness Of Government Masking Mandates On COVID-19 County-Level Case Incidence Across The United States, 2020. <i>Health Affairs</i> , 2022, 41, 445-453.	5.2	27
34	Caspofungin for the Treatment of Pediatric Fungal Infections. <i>Pediatric Infectious Disease Journal</i> , 2008, 27, 1099-1102.	2.0	25
35	Association of Weekend Admission With Hospital Length of Stay, Time to Chemotherapy, and Risk for Respiratory Failure in Pediatric Patients With Newly Diagnosed Leukemia at Freestanding US Children's Hospitals. <i>JAMA Pediatrics</i> , 2014, 168, 925.	6.2	24
36	Suspected posaconazole toxicity in a pediatric oncology patient. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1682-1682.	1.5	24

#	ARTICLE	IF	CITATIONS
37	American Society of Transplantation and Cellular Therapy Series, 2: Management and Prevention of Aspergillosis in Hematopoietic Cell Transplantation Recipients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 201-211.	1.2	23
38	<i>Staphylococcus aureus</i> Bacteremia in Hospitalized Children: Incidence and Outcomes. <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 603-605.	1.8	22
39	Variation in hospital antibiotic prescribing practices for children with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1633-1639.	1.3	21
40	Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1775-1781.	1.5	21
41	Disparities in pediatric acute myeloid leukemia (AML) clinical trial enrollment. <i>Leukemia and Lymphoma</i> , 2019, 60, 2190-2198.	1.3	21
42	A Randomized Trial of Caspofungin vs Triazoles Prophylaxis for Invasive Fungal Disease in Pediatric Allogeneic Hematopoietic Cell Transplant. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 417-425.	1.3	19
43	Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031. <i>Blood</i> , 2019, 134, 292-292.	1.4	19
44	Variation in Risk of Hospital-Onset <i>Clostridium difficile</i> Infection Across $\beta$ -Lactam Antibiotics in Children With New-Onset Acute Lymphoblastic Leukemia. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2014, 3, 329-335.	1.3	18
45	Administration and Dosing of Systemic Antifungal Agents in Pediatric Patients. <i>Paediatric Drugs</i> , 2020, 22, 165-188.	3.1	18
46	A comparison of resource utilization following chemotherapy for acute myeloid leukemia in children discharged versus children that remain hospitalized during neutropenia. <i>Cancer Medicine</i> , 2015, 4, 1356-1364.	2.8	17
47	Opioid utilization among pediatric patients treated for newly diagnosed acute myeloid leukemia. <i>PLoS ONE</i> , 2018, 13, e0192529.	2.5	16
48	Broad-Spectrum Antibiotics and Risk of Graft-versus-Host Disease in Pediatric Patients Undergoing Transplantation for Acute Leukemia: Association of Carbapenem Use with the Risk of Acute Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 177.e1-177.e8.	1.2	16
49	Merging Children's Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children's Oncology Group. <i>PLoS ONE</i> , 2015, 10, e0143480.	2.5	16
50	Establishing a high-risk neuroblastoma cohort using the pediatric health information system database. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1129-1131.	1.5	15
51	A quality improvement initiative to increase pneumococcal vaccination coverage among children after kidney transplant. <i>Pediatric Transplantation</i> , 2016, 20, 783-789.	1.0	15
52	Dexrazoxane Use in Pediatric Patients with Acute Lymphoblastic or Myeloid Leukemia: Analysis of a National Cohort of Patients in the Pediatric Health Information Systems Database From 1999 to 2009. <i>Blood</i> , 2011, 118, 4242-4242.	1.4	15
53	Treatment of Invasive Candidiasis in Immunocompromised Pediatric Patients. <i>Paediatric Drugs</i> , 2008, 10, 281-298.	3.1	14
54	Supportive care utilization and treatment toxicity in children with Down syndrome and acute lymphoid leukaemia at free-standing paediatric hospitals in the United States. <i>British Journal of Haematology</i> , 2016, 174, 591-599.	2.5	14

#	ARTICLE	IF	CITATIONS
55	Chlorhexidine gluconate bathing in children with cancer or those undergoing hematopoietic stem cell transplantation: A double-blind randomized controlled trial from the Children's Oncology Group. <i>Cancer</i> , 2021, 127, 56-66.	4.1	14
56	Prospective Evaluation of Galactomannan and (1 $\alpha$ 3)-D-Glucan Assays as Diagnostic Tools for Invasive Fungal Disease in Children, Adolescents, and Young Adults With Acute Myeloid Leukemia Receiving Fungal Prophylaxis. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 864-871.	1.3	14
57	Cefepime and Mortality in Pediatric Acute Myelogenous Leukemia. <i>Pediatric Infectious Disease Journal</i> , 2009, 28, 971-975.	2.0	13
58	The Role of Biomarkers for Diagnosis of and Therapeutic Decisions Related to Invasive Aspergillosis in Children. <i>Current Fungal Infection Reports</i> , 2013, 7, 7-14.	2.6	13
59	A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group. <i>Leukemia and Lymphoma</i> , 2016, 57, 1567-1574.	1.3	13
60	Cost comparison by treatment arm and center-level variations in cost and inpatient days on the phase III high-risk B acute lymphoblastic leukemia trial AALL0232. <i>Cancer Medicine</i> , 2018, 7, 3-12.	2.8	13
61	Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1184-1189.	1.5	12
62	Treatment of Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 223-229.e2.	0.4	12
63	Human Adenovirus 7-Associated Hemophagocytic Lymphohistiocytosis-like Illness: Clinical and Virological Characteristics in a Cluster of Five Pediatric Cases. <i>Clinical Infectious Diseases</i> , 2021, 73, e1532-e1538.	5.8	12
64	Epidemiology and potential preventative measures for viral infections in children with malignancy and those undergoing hematopoietic cell transplantation. <i>Pediatric Blood and Cancer</i> , 2012, 59, 11-15.	1.5	11
65	Induction mortality, ATRA administration, and resource utilization in a nationally representative cohort of children with acute promyelocytic leukemia in the United States from 1999 to 2009. <i>Pediatric Blood and Cancer</i> , 2014, 61, 68-73.	1.5	11
66	Volume-Outcome Relationships in Pediatric Acute Lymphoblastic Leukemia: Association Between Hospital Pediatric and Pediatric Oncology Volume With Mortality and Intensive Care Resources During Initial Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 404-410.e1.	0.4	11
67	Identification of a novel intertypic recombinant species D human adenovirus in a pediatric stem cell transplant recipient. <i>Journal of Clinical Virology</i> , 2014, 61, 496-502.	3.1	10
68	Hospital Variation in Intensive Care Resource Utilization and Mortality in Newly Diagnosed Pediatric Leukemia*. <i>Pediatric Critical Care Medicine</i> , 2018, 19, e312-e320.	0.5	10
69	Diagnostic Challenges in Pediatric Hemophagocytic Lymphohistiocytosis. <i>Journal of Clinical Immunology</i> , 2021, 41, 1213-1218.	3.8	10
70	Multicenter Prospective Study of Biomarkers for Diagnosis of Invasive Candidiasis in Children and Adolescents. <i>Clinical Infectious Diseases</i> , 2022, 75, 248-259.	5.8	10
71	Pediatric Risk Factors for Candidemia Secondary to <i>Candida glabrata</i> and <i>Candida krusei</i> Species. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2013, 2, 263-266.	1.3	8
72	Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database. <i>Pediatric Blood and Cancer</i> , 2016, 63, 901-907.	1.5	8

#	ARTICLE	IF	CITATIONS
73	Low rates of pregnancy screening in adolescents before teratogenic exposures in a national sample of children's hospitals. <i>Cancer</i> , 2016, 122, 3394-3400.	4.1	8
74	Retrospective review of immunocompromised children undergoing skin biopsy for suspected invasive infection: Analysis of factors predictive of invasive mold. <i>Pediatric Dermatology</i> , 2018, 35, 104-111.	0.9	8
75	A multicenter study to define the epidemiology and outcomes of <i>Clostridioides difficile</i> infection in pediatric hematopoietic cell and solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2020, 20, 2133-2142.	4.7	8
76	Early stool microbiome and metabolome signatures in pediatric patients undergoing allogeneic hematopoietic cell transplantation. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29384.	1.5	8
77	Challenges in the Treatment of Invasive Aspergillosis in Immunocompromised Children. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	3.2	8
78	Burden of Influenza-Related Hospitalizations and Attributable Mortality in Pediatric Acute Lymphoblastic Leukemia. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2015, 4, 290-296.	1.3	7
79	Comparative effectiveness of fungicidal vs. fungistatic therapies for the treatment of paediatric candidaemia. <i>Mycoses</i> , 2016, 59, 173-178.	4.0	7
80	Outcomes of human adenovirus infection and disease in a retrospective cohort of pediatric solid organ transplant recipients. <i>Pediatric Transplantation</i> , 2019, 23, e13510.	1.0	7
81	Identifying patient- and family-centered outcomes relevant to inpatient versus at-home management of neutropenia in children with acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26927.	1.5	6
82	Hospital-Level Variability in Broad-Spectrum Antibiotic Use for Children With Acute Leukemia Undergoing Hematopoietic Cell Transplantation. <i>Infection Control and Hospital Epidemiology</i> , 2018, 39, 797-805.	1.8	6
83	Fatal Neonatal Sepsis Associated with Human Adenovirus Type 56 Infection: Genomic Analysis of Three Recent Cases Detected in the United States. <i>Viruses</i> , 2021, 13, 1105.	3.3	6
84	Medical Outcomes, Quality of Life, and Family Perceptions for Outpatient vs Inpatient Neutropenia Management After Chemotherapy for Pediatric Acute Myeloid Leukemia. <i>JAMA Network Open</i> , 2021, 4, e2128385.	5.9	6
85	Bortezomib Inpatient Prescribing Practices in Free-Standing Children's Hospitals in the United States. <i>PLoS ONE</i> , 2016, 11, e0151362.	2.5	5
86	Creation of a pediatric mature B-cell non-Hodgkin lymphoma cohort within the Pediatric Health Information System Database. <i>PLoS ONE</i> , 2017, 12, e0186960.	2.5	5
87	Complete Versus Staged Repair for Neonates With Tetralogy of Fallot. <i>Medical Care</i> , 2018, 56, e76-e82.	2.4	5
88	Posaconazole Administration in Hospitalized Children in the United States. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2019, 8, 481-484.	1.3	5
89	Effect of first-line biologic initiation on glucocorticoid exposure in children hospitalized with new-onset systemic juvenile idiopathic arthritis: emulation of a pragmatic trial using observational data. <i>Pediatric Rheumatology</i> , 2021, 19, 109.	2.1	5
90	Pneumocystis Pneumonia: Epidemiology and Options for Prophylaxis in Non-HIV Immunocompromised Pediatric Patients. <i>Current Fungal Infection Reports</i> , 2014, 8, 45-55.	2.6	4

#	ARTICLE	IF	CITATIONS
91	Early discharge as a mediator of greater ICU-level care requirements in patients not enrolled on the AAML0531 clinical trial: a Children's Oncology Group report. <i>Cancer Medicine</i> , 2016, 5, 2412-2416.	2.8	4
92	Complications preceding early deaths in Black and White children with acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26712.	1.5	4
93	Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. <i>Haematologica</i> , 2017, 102, e340-e343.	3.5	4
94	Resource utilization and toxicities after single versus tandem autologous stem cell rescue in high-risk neuroblastoma using a national administrative database. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27372.	1.5	4
95	Impact of Trimethoprim-sulfamethoxazole Urinary Tract Infection Prophylaxis on Non-UTI Infections. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 396-397.	2.0	4
96	The epidemiology of rasburicase use in paediatric patients with acute lymphoblastic leukaemia and non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 684-688.	2.5	4
97	Variation in treatment of children hospitalized with new-onset systemic juvenile idiopathic arthritis in the United States. <i>Arthritis Care and Research</i> , 2020, 73, 1714-1721.	3.4	4
98	Musculoskeletal impairments in children receiving intensive therapy for acute leukemia or undergoing hematopoietic stem cell transplant: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29053.	1.5	4
99	Center Variability in Acute Rejection and Biliary Complications After Pediatric Liver Transplantation. <i>Liver Transplantation</i> , 2022, 28, 454-465.	2.4	4
100	Incidence and risk factors for hypoglycemia during maintenance chemotherapy in pediatric acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29467.	1.5	4
101	International Collaborative on Contemporary Epidemiology and Diagnosis of Invasive Fungal Disease in Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2017, 6, S1-S2.	1.3	3
102	Successful treatment of pulmonary mucormycosis in two pediatric hematopoietic stem cell transplant patients. <i>Pediatric Transplantation</i> , 2018, 22, e13270.	1.0	3
103	Comparative Effectiveness of Echinocandins vs Triazoles or Amphotericin B Formulations as Initial Directed Therapy for Invasive Candidiasis in Children and Adolescents. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, , .	1.3	3
104	Rates of Laboratory Adverse Events By Chemotherapy Course for Pediatric Acute Leukemia Patients within the Leukemia Electronic Abstraction of Records Network (LEARN). <i>Blood</i> , 2019, 134, 333-333.	1.4	3
105	Evaluation of resources used during care of children with high-risk neuroblastoma (HR NBL) via merging of cooperative group trial data and administrative data.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10069-10069.	1.6	3
106	Increased Disease Burden Among Black Children Compared to White Children with Newly Diagnosed Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 369-369.	1.4	3
107	Administration of Palivizumab in the NICU. <i>Hospital Pediatrics</i> , 2016, 6, 354-358.	1.3	2
108	The Changing Landscape for Paediatric Regulation of Pharmaceutical Agents with a Focus on Antifungal Agents. <i>Current Fungal Infection Reports</i> , 2016, 10, 1-6.	2.6	2

#	ARTICLE	IF	CITATIONS
109	The Cost of Vancomycin and Piperacillin/Tazobactam Treatmentâ€™Reply. JAMA Pediatrics, 2018, 172, 494.	6.2	2
110	Evaluation of Hospital Admission Patterns in Children Receiving Treatment for Acute Lymphoblastic Leukemia: What Does a Typical Leukemia Experience Look like?. Blood, 2018, 132, 4763-4763.	1.4	2
111	Evolution of SARS-CoV-2 Seroprevalence Among Employees of a United States Academic Childrenâ€™s Hospital During the COVID-19 Pandemic. Infection Control and Hospital Epidemiology, 2021, , 1-24.	1.8	2
112	Antibiotic use in pediatric patients admitted to a referral hospital in Botswana. American Journal of Tropical Medicine and Hygiene, 2009, 81, 129-31.	1.4	2
113	1074Immunization Practices of Pediatric Oncology Providers Towards Children with Acute Lymphoblastic Leukemia that have Completed Chemotherapy. Open Forum Infectious Diseases, 2014, 1, S315-S315.	0.9	1
114	Infectious diseases approach to immunocompromised patients in the pediatric intensive care unit. Journal of Pediatric Intensive Care, 2015, 03, 305-313.	0.8	1
115	Conventional compared to network meta-analysis to evaluate antibiotic prophylaxis in patients with cancer and haematopoietic stem cell transplantation recipients. BMJ Evidence-Based Medicine, 2020, 26, bmjebm-2020-111362.	3.5	1
116	Presentation acuity, induction mortality, and resource utilization in infants with acute leukemia. Pediatric Blood and Cancer, 2021, 68, e28940.	1.5	1
117	Area-Based Socioeconomic Disparities in Survival of Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Blood, 2019, 134, 703-703.	1.4	1
118	Avascular Necrosis(AVN) and Surgical Intervention In Pediatric Acute Lymphoblastic Leukemia(ALL): A Retrospective Cohort Analysis From The Pediatric Health Information Systems (PHIS). Blood, 2013, 122, 1689-1689.	1.4	1
119	Accuracy Of Adverse Event Reporting Compared To Patient Chart Abstraction On a Phase III NCI-Funded Clinical Trial For Pediatric Acute Myeloid Leukemia: A Report From The Childrenâ€™s Oncology Group. Blood, 2013, 122, 931-931.	1.4	1
120	Poverty and survival in targeted immunotherapy clinical trials.. Journal of Clinical Oncology, 2019, 37, 10034-10034.	1.6	1
121	Induction Mortality In Pediatric Acute Lymphoblastic Leukemia (ALL): a Retrospective Cohort Analysis From the Pediatric Health Systems Information (PHIS) Database, 1999â€™2009. Blood, 2010, 116, 3239-3239.	1.4	1
122	Treatment Toxicity and Supportive Care Utilization in Children with Down Syndrome and Acute Lymphoid Leukemia at Free-Standing Pediatric Hospitals in the United States. Blood, 2014, 124, 553-553.	1.4	1
123	Home or Away from Home: A Multi-Institution Study Comparing Medical Outcomes, Patient Perspectives, and Health-Related Quality of Life for Outpatient Versus Inpatient Management after Chemotherapy for Pediatric Acute Myeloid Leukemia. Blood, 2019, 134, 379-379.	1.4	1
124	Assessment of the impact of inpatient infectious events in pediatric patients with newly diagnosed acute leukemia at Dr. Robert Reid Cabral Childrenâ€™s Hospital, Dominican Republic. PLoS ONE, 2020, 15, e0243795.	2.5	1
125	Center Variation in Indication and Short-Term Outcomes after Pediatric Heart Transplantation: Analysis of a Merged United Network for Organ Sharing â€™ Pediatric Health Information System Cohort. Pediatric Cardiology, 2022, 43, 636-644.	1.3	1
126	Risk of bacterial bloodstream infection does not vary by central-line type during neutropenic periods in pediatric acute myeloid leukemia. Infection Control and Hospital Epidemiology, 2023, 44, 222-229.	1.8	1



#	ARTICLE	IF	CITATIONS
127	1444Comparative effectiveness of fungicidal vs fungistatic therapies for the treatment of pediatric candidemia. Open Forum Infectious Diseases, 2014, 1, S380-S380.	0.9	0
128	Management of invasive fungal infections in the pediatric intensive care unit. Journal of Pediatric Intensive Care, 2015, 03, 269-279.	0.8	0
129	A marginal structural approach to measuring the comparative effectiveness of echinocandins Versus fluconazole therapy for the treatment of adult candidemia (MSG-12). Open Forum Infectious Diseases, 2016, 3, .	0.9	0
130	Prophylaxis Against Invasive Fungal Disease for Neutropenic Children and Young Adultsâ€™Reply. JAMA - Journal of the American Medical Association, 2020, 323, 998.	7.4	0
131	Merging of Children's Oncology Group and Pediatric Health Information Systems Data to Determine Resource Utilization and Treatment Costs on AAML0531: A Report From the Children's Oncology Group. Blood, 2011, 118, 2617-2617.	1.4	0
132	Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric cancer patients.. Journal of Clinical Oncology, 2012, 30, 1504-1504.	1.6	0
133	Mortality and Resource Utilization in Children with De Novo Acute Myeloid Leukemia Treated with Chemotherapy and Gemtuzumab Ozogamicin in the United States. Blood, 2012, 120, 4283-4283.	1.4	0
134	Variation in antibiotic use in pediatric acute lymphoblastic leukemia (ALL) by hospital pediatric volume.. Journal of Clinical Oncology, 2014, 32, e17703-e17703.	1.6	0
135	Impact of weekend admission on hospital length of stay and organ failure in pediatric leukemia patients at free-standing U.S. childrenâ€™s hospitals.. Journal of Clinical Oncology, 2014, 32, 6598-6598.	1.6	0
136	Standardized costs and outcome in children treated with gemtuzumab on the AAML0531 trial: A report from the Childrenâ€™s Oncology Group.. Journal of Clinical Oncology, 2014, 32, 7086-7086.	1.6	0
137	Broncho-Alveolar Lavage and Lung Biopsy in Patients with Hematological Malignancy and Hematopoietic Stem Cell Transplantation Recipients: A Systematic Review and Meta-Analysis. Blood, 2014, 124, 2628-2628.	1.4	0
138	ÂResource Utilization and Cost Analysis By Treatment Arm on the Childrenâ€™s Oncology Group AALL0232 Phase 3 High-Risk B-Precursor Acute Lymphoblastic Leukemia Trial: A Report from the Childrenâ€™s Oncology Group. Blood, 2014, 124, 210-210.	1.4	0
139	Accuracy of adverse event reporting on a phase III clinical trial for pediatric acute myeloid leukemia: A report from the Childrenâ€™s Oncology Group.. Journal of Clinical Oncology, 2015, 33, 10028-10028.	1.6	0
140	Resource utilization (RU) and toxicities after carboplatin/etoposide/melphalan (CEM) and busulfan/melphalan (BuMel) for autologous stem cell rescue (ASCR) in high-risk neuroblastoma (HRNB).. Journal of Clinical Oncology, 2015, 33, e21009-e21009.	1.6	0
141	Racial Disparities in Pediatric Acute Myeloid Leukemia during Induction. Blood, 2015, 126, 530-530.	1.4	0
142	Using administrative laboratory result data to describe adverse events.. Journal of Clinical Oncology, 2018, 36, e18698-e18698.	1.6	0
143	Assessing Neighborhood Characteristics As Risk Factors for Bloodstream Infection in Children with Acute Leukemia. Blood, 2018, 132, 833-833.	1.4	0
144	Using Administrative Data to Identify Relapse and Hematopoietic Stem Cell Transplantation (HSCT) in Children with Acute Lymphoblastic Leukemia (ALL): Validation at Two Centers and Incidence Estimation in a National Cohort. Blood, 2018, 132, 624-624.	1.4	0

#	ARTICLE	IF	CITATIONS
145	A Novel Approach to Identifying Septic Shock (SS) in Children with Acute Lymphoblastic Leukemia (ALL) Using Pediatric Health Information System (PHIS) Data: Methods Validation and Incidence Estimation in a National Cohort. <i>Blood</i> , 2018, 132, 3597-3597.	1.4	0
146	Comparative Effectiveness of Rasburicase and Allopurinol in Children with Acute Lymphoblastic Leukemia: An Emulated Pragmatic Trial Using Observational Data. <i>Blood</i> , 2018, 132, 830-830.	1.4	0
147	1745. Retrospective Cohort Analysis to Determine the Incidence of CMV Infection and Disease in Allogeneic Hematopoietic Cell Transplant Recipients at an Academic Children's Hospital. <i>Open Forum Infectious Diseases</i> , 2019, 6, S639-S640.	0.9	0
148	Reduced Relapse Risk in Children with Acute Myeloid Leukemia (AML) Who Experience Septic Shock (SS). <i>Blood</i> , 2019, 134, 3496-3496.	1.4	0
149	Fungal diagnostic testing and therapy: navigating the neutropenic period in children with high-risk leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 361-367.	2.5	0